amylin pharmaceuticals inc diabetes treatment byetta in promising phase iii study amylin pharmaceuticals inc eli lilly &amp co and alkermes inc reported positive preliminary results from a highly anticipated late stage study of the slow release version of diabetes treatment byetta although investors may have been looking for more the results from the week head to head phase iii study showed superiority of the once weekly version called byetta lar over the currently marketed twice daily version byetta lar showed greater reduction in a key measure of glucose than did byetta and both showed identical weight loss both measures of success in managing type diabetes "while the trial was positive we believe that the difference between lar and byetta was somewhat below expectations " wrote phil nadeau a cowen &amp co analyst 
